UPDATED: PBS restrictions on infliximab have been eased for biosimilar brands to allow Streamlined or Telephone Authority for ongoing prescriptions, but only for Crohns disease at the present time. The easing of the restrictions, intended by the government to drive uptake of infliximab biosimilars such as Renflexis and Inflectra, will mean clinicians no longer have ...
PBS restrictions to be lifted on infliximab biosimilars
By Michael Woodhead
10 Jul 2018